Fucoxanthin improves functional recovery of orbitopathy in Graves’ disease by downregulating IL-17 mRNA expression in a mouse model
Purpose: To explore the efficacy of fucoxanthin (FX), a carotenoid, against inflammation via inhibition of IL-17 mRNA expression, and its anti-oxidant activity in Graves’ orbitopathy (GO)-induced mice model.
Methods: The effects of FX on IL-6, IL-8, IL-17, MCP-1, and TNF-α, in orbital fibroblast tissues extracted from GO-induced BALB/c mice was investigated. Anti-oxidative stress markers, 8-hydroxy-2’- deoxyguanosine (8-OHdG) and malondialdehyde (MDA) levels were quantified in tear samples collected from GO-induced FX treated mice.
Results: FX administration in cultured human orbital fibroblast cells revealed almost complete cell viability and no cell apoptosis. FX resulted in IL-1β induced Beclin-1 and Atg-5 silencing, in cultured human orbital fibroblasts. BALB/c mice immunized with Ad-TSHR289 indicated elevated levels of
thyroid peroxidase and thyroglobulin antibodies in the serum sample. FX predominantly downregulated the mRNA expression of IL-17, and also reduced increased 8-OHdG and MDA in the tear secretion of GO-induced mice.
Conclusion: FX may be an effective and useful molecule for the treatment of GO, through its antiinflammatory and anti-oxidative potential, but it requires further investigation to ascertain its therapeutic effectiveness.
Keywords: Anti-inflammatory, Anti-oxidant, Fucoxanthin, Graves’ disease, Graves’ orbitopathy, IL-17
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.